Regulatory Approval

After a decade as a state bank, Jeff Bank is returning to a national charter. This move streamlines regulation and leverages federal law to gain a vital edge.

A new study challenges the federal monopoly on deposit insurance, arguing a private, market-based model offers a more resilient future after 2023's bank failures.

Alkami and Yodlee's new FDX API integration moves beyond risky screen scraping, signaling a major industry shift towards more secure and reliable open banking.

As federal agencies race to adopt AI, Israeli startup Sweet Security aims to secure this new frontier by tackling the rigorous FedRAMP certification.

A new poll shows crypto voters have doubled, but the real story is a deeper anxiety over data privacy that is creating a powerful new political force.

A junior miner revives a historic Utah uranium district, blending old data with new tech. Is this a savvy play for the nuclear boom or a speculative gamble?

With its pivotal Phase 3 trial complete, Rafael Holdings is on a path to redefine treatment for NPC and transform itself into a commercial-stage biotech.

A new deal brings a breakthrough blood cancer therapy, Zemcelpro®, closer to Canada. But for patients with few options, the 2028 timeline is a stark reminder of the gap between innovation and access.

Canada's new Digital Safety Act could ban social media for kids under 16 and create a new regulator. What does this mean for Big Tech's bottom line?

Health Canada's Priority Review for a new Duchenne muscular dystrophy drug signals hope for patients and a strategic test of Canada's rare disease market.

A UK firm's regulatory milestone is more than just compliance; it's a strategic masterclass in building the resilient systems needed to fight food allergies.

How a Swedish city's new aquatic center, powered by unique CO₂ technology, reveals a future where public infrastructure can be both sustainable and strategic.

Mickey Mikitani shifts to Executive Chairman, installing a new CEO to navigate the high-stakes journey from visionary science to U.S. market reality.

Takeda seeks FDA approval for its gut-focused drug ENTYVIO in children, a major step toward a new era of treatment for the rising tide of pediatric IBD.

A partial settlement for California American Water's rates offers a preview of a national dilemma: how to pay for vital upgrades without overburdening consumers.

Ottawa unveils the Safe Social Media Act, proposing an under-16 ban and a new regulator. Will this bold move save kids or stifle innovation?

A new biologic, Nucala, gains Health Canada approval for a specific type of COPD, offering hope for patients and a new strategic frontier for GSK.

A new industry-funded study in Rouyn-Noranda finds diet, not the Horne Smelter, is the main source of arsenic exposure, challenging years of health warnings.

The OSC's latest warning names 11 firms. We dissect their playbook—from clone fraud to AI-driven tactics—to reveal the mechanics of financial resilience.

A new FDA-cleared laser offers a drug-free option for millions with tennis elbow. But does the science justify the cost and will patients have access?